TXG / 10x Genomics, Inc. (TXG) CEO Serge Saxonov on Q2 2022 Results - Earnings Call Transcript

10x Genomics is a life science technology company with a clear mission and visionary leadership. 10x Genomics delivered a solid Q3 quarter with revenu more_horizontal

10x Genomics, Inc. (NASDAQ:TXG ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Cassie Corneau - Director, Investor more_horizontal

Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended September 2023, it might be worth more_horizontal

10x Genomics reported impressive Q2 performance with revenue growing by 28% YoY to reach $147M. The company's growth is driven by strong performance i more_horizontal

While the top- and bottom-line numbers for 10x Genomics (TXG) give a sense of how the business performed in the quarter ended June 2023, it could be w more_horizontal

10x Genomics (TXG) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of more_horizontal

Fintel reports that on July 13, 2023, Goldman Sachs maintained coverage of 10x Genomics Inc – (TXG) with a Sell recommendation. more_horizontal

10x Genomics has been on my Compounding Healthcare “Bio Boom” speculative portfolio watch list since its IPO back in 2019. I believe 10x Genomics more_horizontal